Biomarin Pharmaceutical Inc (BMRN)

Debt-to-equity ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	593,095	1,083,020	1,079,080	1,075,140	486,238
Total stockholders’ equity	US$ in thousands	4,951,550	4,603,160	4,265,670	4,100,930	3,122,380
Debt-to-equity ratio		0.12	0.24	0.25	0.26	0.16

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $593,095K ÷ $4,951,550K
= 0.12

The debt-to-equity ratio of Biomarin Pharmaceutical Inc has shown a decreasing trend over the past five years, indicating a favorable financial position in terms of leverage and capital structure. In 2023, the ratio stands at 0.12, which is significantly lower compared to the previous years. This suggests that the company has been effectively managing its debt levels relative to its equity, potentially reducing financial risk and enhancing overall financial stability. The decreasing trend in the debt-to-equity ratio may indicate that Biomarin Pharmaceutical Inc has been relying more on equity financing rather than debt, which could be perceived positively by investors and creditors. Overall, the lower debt-to-equity ratio reflects a healthier balance between debt and equity and signals a potentially strong financial position for the company.